Navigation Links
Albumin in Medical Technology

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

... alfa-2b is a genetic fusion of human albumin and interferon alfa created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood ... genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of ...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... alfa-2b is a genetic fusion of human albumin and interferon alfa created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood ... genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of ...

InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International

... can replace bovine or human sources of albumin or transferrin and provide better productivity, ... includes: -- Cellastim -- Cellastim is an albumin used to replace bovine albumin and ...

Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C

... alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood ...

Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy

... alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood ...

Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C

... alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood ...

Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule

... alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood ...

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

... Cardiovascular System). Weight, edema, blood pressure, and serum albumin levels should be carefully monitored on an outpatient basis. This syndrome ... or hypotension is the primary clinical problem. Pre-existing low serum albumin levels appear to predict and may predispose patients to the syndrome (see ...

Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care

... IGIV product, octagam(R) (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Based in Lachen, Switzerland, Octapharma employs over 3,000 ...

FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight

... (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. ...

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

... with high peak levels of exenatide exposure observed with injection administration. Unlike other extended delivery technologies such as polymers or albumin fusion, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. Syncria is generated from the genetic fusion of human albumin and GLP-1, a peptide hormone that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. HGS is entitled to ...

Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

... Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information Patients with chronic renal ...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

... prophylaxis. Contraindications -- PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- Patients with chronic renal failure experienced ...

Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions

... prophylaxis. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- The dose of PROCRIT should be titrated for each patient ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... 1) created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. Syncria is generated from the genetic fusion of human albumin and GLP-1, a peptide hormone that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. GSK is developing ...

New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... prophylaxis. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- The dose of PROCRIT should be titrated for each patient ...

Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

... prophylaxis. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- The dose of PROCRIT should be titrated for each patient ...

Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote

... prophylaxis. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- The dose of PROCRIT should be titrated for each patient ...

Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia

... prophylaxis. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- The dose of PROCRIT should be titrated for each patient ...

Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents

... prophylaxis. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- The dose of PROCRIT should be titrated for each patient ...

CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity

... additional data to validate the results seen in our pre-clinical study of this molecule." Today's Presentation: Study Design Genetic fusion to albumin is an efficient way to extend the half-life of small proteins, but so far it has not been successfully used for the half-life extension of complex ...

PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting

... prophylaxis. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- The dose of PROCRIT should be titrated for each patient ...

Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data

... or kidney protecting, drugs, known as the glycosaminoglycans. A variety of members of this chemical family have been shown to decrease pathological albumin excretion in diabetic nephropathy in humans. Some of the members of this chemical family include the following approved drugs: standard heparin, low ...

New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting

... - 12:00 p.m. PST. Exhibit Hall, Moscone Center) -- C.E.R.A. maintains stable hemoglobin (Hb) in chronic kidney disease (CKD), regardless of albumin or dialysis adequacy (Kt/V). W. Sulowicz et al. (Publication Only) -- Effect of baseline hemoglobin (Hb) on Hb stability in patients (pts) ...

Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy

... whether further evaluation of the compound is warranted. Proteinuria, the presence of excess protein in the urine, is an indicator of renal disease. albumin excretion is a risk factor for kidney failure, stroke and cardiovascular and all-cause mortality, particularly in patients with diabetes and/or ...

Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients

... was transient, painless erythema at the site of injection. There was no effect on liver synthetic function as indicated by changes in bilirubin and albumin levels and prothrombin time. Three patients treated with the 300 mg/week dose experienced mild elevations of liver transaminases above three times ...

Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label

... RBC transfusions. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information * Monitor Hb regularly during therapy, more frequently ...

Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine

... RBC transfusions. Contraindications PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products. Additional Important Safety Information -- Monitor Hb regularly during therapy, more frequently ...

Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon

... alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood ...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

... Cardiovascular System). Weight, edema, blood pressure and serum albumin levels should be carefully monitored on an outpatient basis. This syndrome ... or hypotension is the primary clinical problem. Preexisting low serum albumin levels appear to predict and may predispose patients to the syndrome (see ...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

... Research: Results of a Phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum- sensitive patients ... Research Committee: An open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in ...

Haemacure Announces Preliminary Findings of its Plasma Discard Analysis

... concluded Mr. Galli. Haemacure plans on harvesting albumin from this discard and using it in the production of its fibrin sealant, ... estimated at more than US$500,000 at full production plant capacity. Some albumin extracted could also be available for commercialization. According to ...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

... announced that data relating to its proprietary PC-DAC(TM):Exendin-4 albumin Conjugate for the treatment of Type 2 diabetes will be presented at the ... Exendin-4 analogue that is covalently bound to recombinant human albumin (Recombumin(R), provided by Novozymes Delta Limited). Data from Phase I/II ...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine

... hypertension. Neostigmine was most commonly associated (>4%) with prolonged neuromuscular blockade, dry mouth, nausea, procedural complication and albumin present in urine.[1, 2] During the congress, results from three additional Phase III trials – Libra, Spring and Crystal trials - ....

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine

... hypertension. Neostigmine was most commonly associated (>4%) with prolonged neuromuscular blockade, dry mouth, nausea, procedural complication and albumin present in urine.(1),(2) During the congress, results from three additional Phase III trials - Libra, Spring and Crystal trials - were presented. ...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

... or kidney protecting, drugs, known as the glycosaminoglycans. A variety of members of this chemical family have been shown to decrease pathological albumin excretion in diabetic nephropathy in humans. Some of the members of this chemical family include the following approved drugs: standard heparin, low ...
Other Contents
(Date:7/10/2014)... business incubator, received a $1.4 million federal grant to ... staunch bleeding during brain surgery. , Surgeons can spray ... bio-polymer solutions in the gel will cohere and control ... The gel can shorten an intracranial surgery by 30- ... the patient,s skull to be open and less anesthesia, ...
(Date:7/10/2014)... today that Courtney Aldrich, Ph.D., will head the ... as editor-in-chief. With the first issue slated for ... meet a growing demand for a place to ... vision is to develop a journal focused on ... science that advances the field and lays the ...
(Date:7/10/2014)... with a cardiac pacemaker, a low sense of self-competence ... a study in the July Journal of ... of the Society for Developmental and Behavioral Pediatrics ... Williams & Wilkins , a part of Wolters ... protective factor against lower health-related quality of life in ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2ACS Infectious Diseases: Unique chemistry journal names editor 2For children with pacemakers, 'self-competence' affects quality of life 2
(Date:7/10/2014)... Huddersfield could help to improve the quality of some ... as butter, mayonnaise, yoghurt and fruit drinks and ... her work. , Katerina gained her MSc degree in ... she has embarked on research for a PhD. ... investigating the potential of carbohydrates extracted from the pods ...
(Date:7/10/2014)... review identifying the clinical indicators most strongly associated with ... of developing evidence-based guidelines for concussion diagnosis, prognosis, and ... Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... , Based on analysis of the best available research ...
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... Researchers at sarcomas research group at the Bellvitge Biomedical ... (ICO) have been tested in 19 patients a new ... results, which indicate that the new treatment could stabilize ... week in the British Journal of Cancer ., ... tumor and complex since there are several subtypes. It ...
(Date:7/10/2014)... that a new drug could prove useful in treating small ... cancer. , Scientists from the Cancer Research UK Manchester Institute, ... Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, ... a drug known as AZD3965 - on small cell ... Clinical Cancer Research , also helps identify which patients ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2
Other TagsOther Tags